De Novo device
Fibresolve (with PCCP)
Imvaria, Inc. · Radiology Software For Referral Of Findings Related To Fibrotic Lung Disease. (QWO, Class II) · First FDA decision Jan 12, 2024, newest Nov 7, 2025
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
0
Naming "Fibresolve"
MAUDE reports
0
Brand "Fibresolve", since 2015
PubMed studies
8
Mentioning "Fibresolve"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Fibresolve (with PCCP)510(k)
K252041 · Decided Nov 7, 2025 · 130 days after receipt
Device type: Radiology Software For Referral Of Findings Related To Fibrotic Lung Disease. (QWO) · Radiology & Imaging
- FibresolveNew device typeBreakthroughDe Novo
DEN220040 · Decided Jan 12, 2024 · 562 days after receipt
Device type: Radiology Software For Referral Of Findings Related To Fibrotic Lung Disease. (QWO) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hospice Alzheimer's Disease & Related DisordersLocal determinationIn effectL34567Palmetto GBAUpdated Feb 23, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Fibresolve", any status and sponsor, newest update first.
No registered device study names "Fibresolve".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Fibresolve", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QWO
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Fibresolve"[tiab]. The summary above synthesizes these.
- Computed tomography machine learning classifier correlates with mortality in interstitial lung disease.
Moran-Mendoza O, Singla A, Kalra A, et al. · Respir Investig · 2024
- A Machine Learning System to Indicate Diagnosis of Idiopathic Pulmonary Fibrosis Non-Invasively in Challenging Cases.
Ahmad Y, Mooney J, Allen IE, et al. · Diagnostics (Basel) · 2024
- Machine learning classifier is associated with mortality in interstitial lung disease: a retrospective validation study leveraging registry data.
Selvan KC, Reicher J, Muelly M, et al. · BMC Pulm Med · 2024Multicenter Study, Validation Study
- Multi-modal machine learning classifier for idiopathic pulmonary fibrosis predicts mortality in interstitial lung diseases.
Callahan SJ, Scholand MB, Kalra A, et al. · Respir Investig · 2025
- Analysis of Validation Performance of a Machine Learning Classifier in Interstitial Lung Disease Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on CT Using Clinical and Pathology-Supported Diagnostic Labels.
Chang M, Reicher JJ, Kalra A, et al. · J Imaging Inform Med · 2024
- Clinical Utility of an FDA-Authorized Artificial Intelligence Imaging Platform in Interstitial Lung Disease Diagnosis.
Tambe AP, Boente RD, George G, et al. · Diagnostics (Basel) · 2026
- Paired Validation of a Multimodal Vision-Transformer System for the Non-Invasive Diagnosis of Idiopathic Pulmonary Fibrosis.
Tahamtani-Omran O, Kalra A, Muelly M, et al. · Diagnostics (Basel) · 2026
- External validation of Fibresolve, a machine-learning algorithm, to non-invasively diagnose idiopathic pulmonary fibrosis.
Bradley J, Huang J, Kalra A, et al. · Am J Med Sci · 2024
Other devices of this type
Also filed under product code QWO.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.